Myoblast-Derived Galectin 3 Impairs the Early Phases of Osteogenesis Affecting Notch and Akt Activity
<p>Muscle differentiation and mechanical stimulation trigger Gal-3 expression and release. (<b>A</b>) The C2C12 cells were differentiated for the indicated days. At the end of each time point, the cells and culture media were collected. The cells were lysed and, together with the culture media, were resolved by SDS-PAGE and explored for the Gal-3 level of expression. β-Tubulin and MyoD were used as loading and differentiation markers, respectively. Original images can be found in <a href="#app1-biomolecules-14-01243" class="html-app">Supplementary File 1</a>. (<b>B</b>) The densitometric values of intracellular and secreted Gal-3 were graphed in the bar histogram, shown aside. The densitometric results were normalized on the values of corresponding β-tubulin. * <span class="html-italic">p</span> < 0.05, ** <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.001. (<b>C</b>,<b>D</b>) The differentiated C2C12 cells were subjected to multiaxial stretching (st) for 6 and 24 h, or left untreated (nt). At the end of the stimuli, the cells were lysed and, together with corresponding media, were subjected to an immunoblot analysis to verify the Gal-3 expression. The bars are relative to three different experiments, * <span class="html-italic">p</span> < 0.05, ** <span class="html-italic">p</span> < 0.01. (<b>E</b>) The cells, as in (<b>C</b>), were lysed in Trizol and subjected to an RT-PCR analysis for monitoring the level of expression of Gal-3 mRNA. The bars show the relative amount of Gal-3 mRNA. (<span class="html-italic">n</span> = 3 *** <span class="html-italic">p</span> ≤ 0.001). Original images can be found in <a href="#app1-biomolecules-14-01243" class="html-app">Supplementary File 1</a>.</p> "> Figure 2
<p>Endurance training increases Gal-3 expression in muscle fibers of type IIB. (<b>A</b>,<b>B</b>) The tibialis anterior muscles from the sedentary (Sed) and trained (Tr) mice groups were analyzed to determine the intracellular level of Gal-3 expression. The bar graph represents the average OD of the samples of the two groups, normalized to the corresponding values of GAPDH. Original images can be found in <a href="#app1-biomolecules-14-01243" class="html-app">Supplementary File 1</a>. (<b>C</b>,<b>D</b>) A Gal-3 immunohistochemical analysis of the red (RTA) and white fibers (WTA) of the tibialis anterior muscles from the sedentary and trained mice groups with the images’ signal intensity quantification. (<b>E</b>,<b>F</b>) The Gal-3 immunohistochemical analysis of the red (RGA) and white fibers (WGA) of the gastrocnemius muscles from the sedentary and trained mice groups, with the images’ signal intensity quantification. Enlarged areas are present within the most significant panels. Bars 250 micron. A statistically significant increase in Gal-3 expression was seen in the white fibers of both muscle types in the trained mice group (<span class="html-italic">n</span> = 3, * <span class="html-italic">p</span> < 0.05), when compared to the group of sedentary mice.</p> "> Figure 3
<p>Gal-3 secreted by C2C12 cells impairs the osteogenic potential of the MC-3T3 osteoblast progenitor cells as a recombinant and as the soluble form of Gal-3. (<b>A</b>,<b>B</b>) The MC-3T3 cells were differentiated in the presence of a recombinant soluble form of Gal-3 (rec-Gal-3, FC 3 microg/mL) or another vehicle (vehicle) (<span class="html-italic">n</span> = 3, * <span class="html-italic">p</span> < 0.05, ** <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.001) for three or seven days (D3 and D7, respectively). Where indicated, a combination of rec-Gal-3 and a specific antibody against Gal-3 was added (Gal-3 Ab, rabbit anti-Gal-3 1 µg/mL FC 3 µg/mL). As control, the MC-3T3 osteoblast progenitors were also collected at D0. The matrix bone mineralization was analyzed by alizarin red (AR) staining. After staining, the alizarin was diluted, quantified as described in the “Methods” Section, and the values were presented as a graph (<span class="html-italic">n</span> = 3, *** <span class="html-italic">p</span> < 0.001). (<b>C</b>) The MC-3T3 osteoblast progenitors differentiated in the presence of rec-Gal-3 or another vehicle were harvested at D0, D3, and D7 and collected. One half of the cells’ pellet was then lysed and the total lysates were resolved and assayed for bone-alkaline phosphatase (ALP) and the Osterix level of expression. GAPDH was used as equal loading control. Original images can be found in <a href="#app1-biomolecules-14-01243" class="html-app">Supplementary File 1</a>. (<b>D</b>–<b>F</b>) The densitometric analysis of the level of expression of ALP and Osterix, normalized to GAPDH. (<b>E</b>) The other half of the cell pellets were lysed, and the ALP activity was monitored (<span class="html-italic">n</span> = 3, ** <span class="html-italic">p</span> ≤ 0.01). (<b>G</b>,<b>H</b>) The MC-3T3 osteoblast progenitors differentiated in the presence of rec-Gal-3 or another vehicle were harvested at D0, D3, and D7, lysed, and evaluated for Notch1 and cleaved Notch1 protein expression; a densitometric analysis was carried out, normalized on GAPDH levels, ** <span class="html-italic">p</span> ≤ 0.01. Original images can be found in <a href="#app1-biomolecules-14-01243" class="html-app">Supplementary File 1</a>. (<b>I</b>) The graph bar of the fold change of the level of expression of <span class="html-italic">Hey1</span> and <span class="html-italic">c-Myc</span> RNAs in D0- and D3-differentiated cells (with or without rec-Gal-3), relative to three different experiments (<span class="html-italic">n</span> = 3, * <span class="html-italic">p</span> < 0.05, ** <span class="html-italic">p</span> ≤ 0.01). HPRT was used as a normalization housekeeping gene. (<b>J</b>,<b>K</b>) The MC-3T3 osteoblast precursor cells were maintained in the growth medium D0 and induced to differentiate in a canonical differentiation medium, D7, supplemented with the supernatant from the C2C12 cells that were overexpressing FLAG-Gal-3 (FLAG-Gal-3 OE, transfected for 48 h) or, as a control, from the C2C12 cells transfected with the empty vector (EV, transfected for 48 h). The differentiation medium (D7) was conditioned with the same amount of the C2C12 medium (EV and FLAG-Gal-3) in a medium ratio of 1:3. Samples were collected on the day of the change of the medium, D0, or at D7. The matrix bone mineralization was analyzed by alizarin red (AR) staining. The graph bars indicate the amount of AR staining (<span class="html-italic">n</span> = 3, *** <span class="html-italic">p</span> < 0.001). (<b>L</b>) The MC-3T3 osteoblast progenitors were induced to differentiate in a canonical differentiation medium, D3, supplemented with the supernatant from the C2C12 cells that were subjected or not to a stretching protocol for 6 h. The differentiation medium (D3) was conditioned with one of the three C2C12 media (C2C12 media: not stretched, stretched for 6 h, or stretched for 6 h + neutralizing antibody). The total lysates were resolved and assayed for the bone-alkaline phosphatase (ALP) level of activity (<span class="html-italic">n</span> = 3, * <span class="html-italic">p</span> < 0.05, ** <span class="html-italic">p</span> ≤ 0.01). (<b>M</b>) An RT-qPCR analysis of RUNX2 expression in the MC-3T3 cells differentiated as in M) (<span class="html-italic">n</span> = 3, ** <span class="html-italic">p</span> ≤ 0.01).</p> "> Figure 4
<p>Rec-Gal-3 modulates the expression of proteins with fundamental cellular functions during the differentiation of MC-3T3 osteoprogenitor cells. (<b>A</b>) A Venn diagram showing the proteins identified by an LC-MS analysis. We identified 117 proteins on D0, 366 on D3, and 353 on D3 + rec-Gal-3. (<b>B</b>) The list of proteins up- or down-regulated in the MC-3T3 cells after 3 days of differentiation with recombinant Gal-3, compared to D3. Only the proteins identified with a fold increase ≥ 4 were reported.</p> "> Figure 5
<p>Mechanistic insights into circulating Gal-3 functions during the differentiation of MC-3T3 osteoprogenitor cells. (<b>A</b>) Heat map showing the phosphorylation of the main signaling pathways detected by the RPPA analysis during the growing state (D0), the early (D3), and the middle (D7) phases of the differentiation of the MC-3T3 cells with or without rec-Gal-3. Squared phosphorylated proteins are the species most impaired by Gal-3 supplementation. The values are reported as the mean of signal intensities, with <span class="html-italic">n</span> = 3. (<b>B</b>) The level of expression of the proteins promoting osteogenesis during the differentiation of the MC-3T3 cells with or without rec-Gal-3 (+rec-Gal-3) through the “Bone Metabolism Antibody Array”. The cells were blocked on D0 and D3 (<span class="html-italic">n</span> = 3, * <span class="html-italic">p</span> ≤ 0.05; ** <span class="html-italic">p</span> ≤ 0.01).</p> "> Figure 6
<p>rec-Gal-3 affects the ability of differentiated osteoblasts to interact with ECM components. The evaluation of the ability of the MC-3T3 cells maintained in a growth medium (D0), differentiated for 3 days (D3) with or without recombinant Gal-3 (D3 + rec-Gal-3) to interact with the typical components of the extracellular bone matrix (Collagen I, Fibronectin, Laminin) through the “ECM adhesion assay” (<span class="html-italic">n</span> = 2, * <span class="html-italic">p</span> ≤ 0.05; ** <span class="html-italic">p</span> ≤ 0.01).</p> ">
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cell Cultures and Treatments
2.2. Mice Endurance Training
2.3. RT-PCR
2.4. Protein Assays
2.5. Mass Spectrometry Analysis
2.6. Image Processing and Statistical Analysis
3. Results
3.1. Myogenic Differentiation and Mechanical Stress Trigger Muscle Cells to Produce and Release Galectin 3
3.2. Gal-3 Secreted from Muscle Cells Reduces the Osteogenic Potential of MC-3T3 Cells
3.3. Proteomic Dynamics Induced by Rec-Gal-3 during Osteogenic Differentiation
3.4. The Analysis of the Signaling Pathways Activated by Rec-Gal-3 during Osteogenic Differentiation
3.5. Gal-3 Inhibited Bone Morphogenetic-Dependent Signaling and Counteracted the Adhesion of Osteoblasts to ECM Proteins
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Wohl, G.R.; Boyd, S.K.; Judex, S.; Zernicke, R.F. Functional adaptation of bone to exercise and injury. J. Sci. Med. Sport. 2000, 3, 313–324. [Google Scholar] [CrossRef] [PubMed]
- Regan, J.; Long, F. Notch signaling and bone remodeling. Curr. Osteoporos. Rep. 2013, 11, 126–129. [Google Scholar] [CrossRef] [PubMed]
- Houschyar, K.S.; Tapking, C.; Borrelli, M.R.; Popp, D.; Duscher, D.; Maan, Z.N.; Chelliah, M.P.; Li, J.; Harati, K.; Wallner, C.; et al. Wnt Pathway in Bone Repair and Regeneration—What Do We Know So Far. Front. Cell Dev. Biol. 2018, 6, 170. [Google Scholar] [CrossRef]
- Crane, J.L.; Xian, L.; Cao, X. Role of TGF-beta Signaling in Coupling Bone Remodeling. Methods Mol. Biol. 2016, 1344, 287–300. [Google Scholar]
- Kim, J.M.; Yang, Y.S.; Park, K.H.; Oh, H.; Greenblatt, M.B.; Shim, J.H. The ERK MAPK Pathway Is Essential for Skeletal Development and Homeostasis. Int. J. Mol. Sci. 2019, 20, 1803. [Google Scholar] [CrossRef]
- Tsourdi, E.; Colditz, J.; Lademann, F.; Rijntjes, E.; Kohrle, J.; Niehrs, C.; Hofbauer, L.C.; Rauner, M. The Role of Dickkopf-1 in Thyroid Hormone-Induced Changes of Bone Remodeling in Male Mice. Endocrinology 2019, 160, 664–674. [Google Scholar] [CrossRef] [PubMed]
- Severinsen, M.C.K.; Pedersen, B.K. Muscle-Organ Crosstalk: The Emerging Roles of Myokines. Endocr. Rev. 2020, 4, 594–609. [Google Scholar] [CrossRef]
- Lee, J.H.; Jun, H.S. Role of Myokines in Regulating Skeletal Muscle Mass and Function. Front. Physiol. 2019, 30, 42. [Google Scholar] [CrossRef]
- Magaro, M.S.; Bertacchini, J.; Florio, F.; Zavatti, M.; Poti, F.; Cavani, F.; Amore, E.; De Santis, I.; Bevilacqua, A.; Reggiani Bonetti, L.; et al. Identification of Sclerostin as a Putative New Myokine Involved in the Muscle-to-Bone Crosstalk. Biomedicines 2021, 12, 71. [Google Scholar] [CrossRef]
- Yang, R.Y.; Rabinovich, G.A.; Liu, F.T. Galectins: Structure, function and therapeutic potential. Expert. Rev. Mol. Med. 2008, 13, e17. [Google Scholar] [CrossRef]
- Johannes, L.; Jacob, R.; Leffler, H. Galectins at a glance. J. Cell Sci. 2018, 131, jcs208884. [Google Scholar] [CrossRef] [PubMed]
- Cummings, R.D.; Liu, F.T.; Vasta, G.R. Galectins. In Essentials of Glycobiology [Internet], 3rd ed.; Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., Prestegard, J.H., et al., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2015–2017; Chapter 36. [Google Scholar]
- Banfer, S.; Schneider, D.; Dewes, J.; Strauss, M.T.; Freibert, S.A.; Heimerl, T.; Maier, U.G.; Elsasser, H.P.; Jungmann, R.; Jacob, R. Molecular mechanism to recruit galectin-3 into multivesicular bodies for polarized exosomal secretion. Proc. Natl. Acad. Sci. USA 2018, 115, E4396–E4405. [Google Scholar] [CrossRef] [PubMed]
- Boscher, C.; Zheng, Y.Z.; Lakshminarayan, R.; Johannes, L.; Dennis, J.W.; Foster, L.J.; Nabi, I.R. Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J. Biol. Chem. 2012, 287, 32940–32952. [Google Scholar] [CrossRef] [PubMed]
- Boscher, C.; Nabi, I.R. Galectin-3- and phospho-caveolin-1-dependent outside-in integrin signaling mediates the EGF motogenic response in mammary cancer cells. Mol. Biol. Cell 2013, 24, 2134–2145. [Google Scholar] [CrossRef]
- Slack, R.J.; Mills, R.; Mackinnon, A.C. The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int. J. Biochem. Cell Biol. 2021, 130, 105881. [Google Scholar] [CrossRef]
- Chen, H.Y.; Fermin, A.; Vardhana, S.; Weng, I.C.; Lo, K.F.; Chang, E.Y.; Maverakis, E.; Yang, R.Y.; Hsu, D.K.; Dustin, M.L.; et al. Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc. Natl. Acad. Sci. USA 2009, 106, 14496–14501. [Google Scholar] [CrossRef]
- Nguyen, M.N.; Su, Y.; Vizi, D.; Fang, L.; Ellims, A.H.; Zhao, W.B.; Kiriazis, H.; Gao, X.M.; Sadoshima, J.; Taylor, A.J.; et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci. Rep. 2018, 8, 8213. [Google Scholar] [CrossRef]
- Stock, M.; Schäfer, H.; Stricker, S.; Gross, G.; Mundlos, S.; Otto, F. Expression of galectin-3 in skeletal tissues is controlled by Runx2. J. Biol. Chem. 2003, 278, 17360–17367. [Google Scholar] [CrossRef]
- Weilner, S.; Keider, V.; Winter, M.; Harreither, E.; Salzer, B.; Weiss, F.; Schraml, E.; Messner, P.; Pietschmann, P.; Hildner, F. Vesicular Galectin-3 levels decrease with donor age and contribute to the reduced osteo-inductive potential of human plasma derived extracellular vesicles. Aging 2016, 8, 16–33. [Google Scholar] [CrossRef]
- Nakajima, K.; Kho, D.H.; Yanagawa, T.; Harazono, Y.; Gao, X.; Hogan, V.; Raz, A. Galectin-3 inhibits osteoblast differentiation through notch signaling. Neoplasia 2014, 16, 939–949. [Google Scholar] [CrossRef]
- Park, G.B.; Kim, D.J.; Kim, Y.S.; Lee, H.K.; Kim, C.W.; Hur, D.Y. Silencing of galectin-3 represses osteosarcoma cell migration and invasion through inhibition of FAK/Src/Lyn activation and beta-catenin expression and increases susceptibility to chemotherapeutic agents. Int. J. Oncol. 2015, 46, 185–194. [Google Scholar] [CrossRef] [PubMed]
- Herrador-Canete, G.; Zalacain, M.; Labiano, S.; Laspidea, V.; Puigdelloses, M.; Marrodan, L.; Garcia-Moure, M.; Gonzalez-Huarriz, M.; Marco-Sanz, J.; Ausejo-Mauleon, I.; et al. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma. Mol. Ther. Oncolytics 2022, 26, 246–264. [Google Scholar] [CrossRef] [PubMed]
- Barone, R.; Macaluso, F.; Sangiorgi, C.; Campanella, C.; Marino Gammazza, A.; Moresi, V.; Coletti, D.; Conway de Macario, E.; Macario, A.J.; Cappello, F.; et al. Skeletal muscle Heat shock protein 60 increases after endurance training and induces peroxisome proliferator-activated receptor gamma coactivator 1 alpha1 expression. Sci. Rep. 2016, 6, 19781. [Google Scholar] [CrossRef] [PubMed]
- Piazzi, M.; Kojic, S.; Capanni, C.; Stamenkovic, N.; Bavelloni, A.; Marin, O.; Lattanzi, G.; Blalock, W.; Cenni, V. Ectopic Expression of Ankrd2 Affects Proliferation, Motility and Clonogenic Potential of Human Osteosarcoma Cells. Cancers 2021, 13, 174. [Google Scholar] [CrossRef]
- Signore, M.; Manganelli, V. Reverse Phase Protein Arrays in cancer stem cells. Methods Cell Biol. 2022, 171, 33–61. [Google Scholar]
- Perez-Riverol, Y.; Bai, J.; Bandla, C.; García-Seisdedos, D.; Hewapathirana, S.; Kamatchinathan, S.; Vizcaíno, J.A. The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022, 50, D543–D552. [Google Scholar] [CrossRef]
- Gries, K.J.; Zysik, V.S.; Jobe, T.K.; Griffin, N.; Leeds, B.P.; Lowery, J.W. Muscle-derived factors influencing bone metabolism. Semin. Cell Dev. Biol. 2022, 123, 57–63. [Google Scholar] [CrossRef]
- Hattasch, R.; Spethmann, S.; de Boer, R.A.; Ruifrok, W.P.; Schattke, S.; Wagner, M.; Schroeckh, S.; Durmus, T.; Schimke, I.; Sanad, W.; et al. Galectin-3 increase in endurance athletes. Eur. J. Prev. Cardiol. 2014, 21, 1192–1199. [Google Scholar] [CrossRef]
- Yu, J.; Canalis, E. Notch and the regulation of osteoclast differentiation and function. Bone 2020, 138, 115474. [Google Scholar] [CrossRef]
- Guo, Y.C.; Zhang, S.W.; Yuan, Q. Deubiquitinating Enzymes and Bone Remodeling. Stem Cells Int. 2018, 2018, 3712083. [Google Scholar] [CrossRef]
- Bloemberg, D.; Quadrilatero, J. Rapid determination of myosin heavy chain expression in rat, mouse, and human skeletal muscle using multicolor immunofluorescence analysis. PLoS ONE 2012, 7, e35273. [Google Scholar] [CrossRef] [PubMed]
- Nakajima, K.; Kho, D.H.; Yanagawa, T.; Zimel, M.; Heath, E.; Hogan, V.; Raz, A. Galectin-3 in bone tumor microenvironment: A beacon for individual skeletal metastasis management. Cancer Metastasis Rev. 2016, 35, 333–346. [Google Scholar] [CrossRef] [PubMed]
- Zhou, S.; Dai, Q.; Huang, X.; Jin, A.; Yang, Y.; Gong, X.; Xu, H.; Gao, X.; Jiang, L. STAT3 is critical for skeletal development and bone homeostasis by regulating osteogenesis. Nat. Commun. 2021, 12, 6891. [Google Scholar] [CrossRef] [PubMed]
- Sedlar, A.; Travnickova, M.; Bojarova, P.; Vlachova, M.; Slamova, K.; Kren, V.; Bacakova, L. Interaction between Galectin-3 and Integrins Mediates Cell-Matrix Adhesion in Endothelial Cells and Mesenchymal Stem Cells. Int. J. Mol. Sci. 2021, 22, 5144. [Google Scholar] [CrossRef]
- Bertacchini, J.; Magaro, M.S.; Poti, F.; Palumbo, C. Osteocytes Specific GSK3 Inhibition Affects In Vitro Osteogenic Differentiation. Biomedicines 2018, 6, 61. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Amore, E.; Cenni, V.; Piazzi, M.; Signore, M.; Orlandi, G.; Neri, S.; Biressi, S.; Barone, R.; Di Felice, V.; Follo, M.Y.; et al. Myoblast-Derived Galectin 3 Impairs the Early Phases of Osteogenesis Affecting Notch and Akt Activity. Biomolecules 2024, 14, 1243. https://doi.org/10.3390/biom14101243
Amore E, Cenni V, Piazzi M, Signore M, Orlandi G, Neri S, Biressi S, Barone R, Di Felice V, Follo MY, et al. Myoblast-Derived Galectin 3 Impairs the Early Phases of Osteogenesis Affecting Notch and Akt Activity. Biomolecules. 2024; 14(10):1243. https://doi.org/10.3390/biom14101243
Chicago/Turabian StyleAmore, Emanuela, Vittoria Cenni, Manuela Piazzi, Michele Signore, Giulia Orlandi, Simona Neri, Stefano Biressi, Rosario Barone, Valentina Di Felice, Matilde Y. Follo, and et al. 2024. "Myoblast-Derived Galectin 3 Impairs the Early Phases of Osteogenesis Affecting Notch and Akt Activity" Biomolecules 14, no. 10: 1243. https://doi.org/10.3390/biom14101243
APA StyleAmore, E., Cenni, V., Piazzi, M., Signore, M., Orlandi, G., Neri, S., Biressi, S., Barone, R., Di Felice, V., Follo, M. Y., Bertacchini, J., & Palumbo, C. (2024). Myoblast-Derived Galectin 3 Impairs the Early Phases of Osteogenesis Affecting Notch and Akt Activity. Biomolecules, 14(10), 1243. https://doi.org/10.3390/biom14101243